SOURCE: Nutra Pharma Corp.

May 03, 2006 10:54 ET

The Jalma Institute Signs Purchase Agreement for Nutra Pharma's NTM Test Kits

BOYNTON BEACH, FL -- (MARKET WIRE) -- May 3, 2006 -- Nutra Pharma Corp., (OTC BB: NPHC) a biotechnology company that is developing drugs for HIV and Multiple Sclerosis, has announced that Designer Diagnostics, a wholly owned subsidiary of Nutra Pharma, has received orders from Dr. V. M. Katoch for the NTM Diagnostic TestKits designed for the rapid identification of NonTuberculosis Mycobacterium (NTM). Dr. Katoch is the director of the Central JALMA Institute of Leprosy and other Mycobacterial Diseases. The Institute was founded in 1976 and is currently a leading institute for leprosy and mycobacterial research.

"We are very excited about working with Dr. Katoch and his organization," commented Neil Roth, President of Designer Diagnostics. "We believe that the Designer Diagnostics NTM Test Kits will add tremendous value to the research that is being conducted in India. Our team will continue to work closely with Dr. Katoch to ensure the future success and performance of the test kit technology," he added.

"We believe that the NTM Test Kits address a huge market for Designer Diagnostics," explained Rik J Deitsch, Nutra Pharma's CEO. "NTMs and Tuberculosis (TB) account for the majority of deaths in HIV/AIDS patients. The occurrence of NTMs is dramatically increasing as the number of HIV/AIDS and other immuno-suppressed patients increase. There are currently more than 40 million people around the world who should be tested for these diseases," he concluded.

The first shipments of the NTM Test Kits have been delivered to the Institute. These sales represent the first revenue generated by Designer Diagnostics and Nutra Pharma Corporation.

About The Central JALMA Institute of Leprosy and other Mycobacterial Diseases

The Central JALMA Institute for Leprosy was founded in 1976 and has become a leader in all important aspects of leprosy and mycobacterial research, with focuses on leprosy, relevant areas of tuberculosis and other mycobacteriosis, HIV and Filariasis. The Institute's current director, Dr. V. M. Katoch, is a world-renowned scientist with over 25 years of experience working on microbiology and molecular biology of mycobacterial diseases. Dr. Katoch has written and published over 170 papers on molecular biology.

About Nutra Pharma Corp.

Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's holding, ReceptoPharm, Inc, is developing technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The sale of the NTM kits should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Contact Information